(PATH) Uipath - Ratings and Ratios
Automation, Robots, Cloud, AI
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 79.7% |
| Value at Risk 5%th | 121% |
| Relative Tail Risk | -7.77% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.65 |
| Alpha | 8.00 |
| CAGR/Max DD | 0.22 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.486 |
| Beta | 1.409 |
| Beta Downside | 1.214 |
| Drawdowns 3y | |
|---|---|
| Max DD | 63.58% |
| Mean DD | 33.04% |
| Median DD | 38.30% |
Description: PATH Uipath November 06, 2025
UiPath Inc. (NYSE:PATH) offers a comprehensive automation platform that combines robotic process automation (RPA) with embedded AI, machine learning, and natural-language processing to let enterprises design end-to-end workflows using low-code, drag-and-drop tools. The solution spans UI automation, API integration, and AI-driven document understanding, and is delivered via a multi-tenant cloud architecture that provides built-in security, governance, and rapid deployment without on-premise infrastructure.
In its most recent fiscal year, UiPath reported revenue of approximately $1.9 billion, representing a year-over-year growth rate of roughly 30%, and an annual recurring revenue (ARR) run-rate near $2.1 billion. The company’s gross margin stayed above 80%, while churn on its subscription base remained under 5%, indicating strong customer retention and pricing power in the high-growth RPA market.
The RPA sector is being propelled by a projected compound annual growth rate of about 20% through 2029, driven by accelerating digital transformation initiatives, rising labor cost pressures, and increasing regulatory compliance demands across financial services, healthcare, manufacturing, retail, and the public sector-all core verticals for UiPath. Additionally, macro-economic trends such as tighter labor markets and the push for AI-augmented productivity are expanding the addressable market for automation platforms.
For a deeper, data-driven assessment of UiPath’s valuation metrics and competitive positioning, you may find ValueRay’s analytical dashboards useful as a next step in your research.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (229.7m TTM) > 0 and > 6% of Revenue (6% = 93.2m TTM) |
| FCFTA 0.11 (>2.0%) and ΔFCFTA -0.84pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 78.43% (prev 104.9%; Δ -26.51pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 334.9m > Net Income 229.7m (YES >=105%, WARN >=100%) |
| Net Debt (-671.6m) to EBITDA (25.9m) ratio: -25.89 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.54 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (544.7m) change vs 12m ago -3.24% (target <= -2.0% for YES) |
| Gross Margin 83.16% (prev 83.20%; Δ -0.04pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 55.87% (prev 52.99%; Δ 2.88pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.57 (EBITDA TTM 25.9m / Interest Expense TTM -40.1m) >= 6 (WARN >= 3) |
Altman Z'' -1.15
| (A) 0.42 = (Total Current Assets 2.01b - Total Current Liabilities 788.7m) / Total Assets 2.90b |
| (B) -0.63 = Retained Earnings (Balance) -1.81b / Total Assets 2.90b |
| (C) 0.01 = EBIT TTM 22.7m / Avg Total Assets 2.78b |
| (D) -1.83 = Book Value of Equity -1.78b / Total Liabilities 971.4m |
| Total Rating: -1.15 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 63.42
| 1. Piotroski 6.0pt |
| 2. FCF Yield 3.60% |
| 3. FCF Margin 20.06% |
| 4. Debt/Equity 0.04 |
| 5. Debt/Ebitda -25.89 |
| 6. ROIC - WACC (= -7.92)% |
| 7. RoE 12.88% |
| 8. Rev. Trend 84.15% |
| 9. EPS Trend 62.63% |
What is the price of PATH shares?
Over the past week, the price has changed by +36.61%, over one month by +35.85%, over three months by +63.47% and over the past year by +24.45%.
Is PATH a buy, sell or hold?
- Strong Buy: 3
- Buy: 1
- Hold: 18
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the PATH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15.9 | -17.4% |
| Analysts Target Price | 15.9 | -17.4% |
| ValueRay Target Price | 20.3 | 5.2% |
PATH Fundamental Data Overview December 07, 2025
P/E Trailing = 44.4524
P/E Forward = 20.3666
P/S = 6.4317
P/B = 4.1
P/EG = 0.5816
Beta = 1.1
Revenue TTM = 1.55b USD
EBIT TTM = 22.7m USD
EBITDA TTM = 25.9m USD
Long Term Debt = 77.8m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 3.59m USD (from shortTermDebt, last fiscal year)
Debt = 72.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -671.6m USD (from netDebt column, last quarter)
Enterprise Value = 8.66b USD (9.99b + Debt 72.0m - CCE 1.40b)
Interest Coverage Ratio = -0.57 (Ebit TTM 22.7m / Interest Expense TTM -40.1m)
FCF Yield = 3.60% (FCF TTM 311.6m / Enterprise Value 8.66b)
FCF Margin = 20.06% (FCF TTM 311.6m / Revenue TTM 1.55b)
Net Margin = 14.79% (Net Income TTM 229.7m / Revenue TTM 1.55b)
Gross Margin = 83.16% ((Revenue TTM 1.55b - Cost of Revenue TTM 261.6m) / Revenue TTM)
Gross Margin QoQ = 83.26% (prev 82.20%)
Tobins Q-Ratio = 2.99 (Enterprise Value 8.66b / Total Assets 2.90b)
Interest Expense / Debt = 25.19% (Interest Expense 18.1m / Debt 72.0m)
Taxrate = -708.6% (out of range, set to none) (-174.2m / 24.6m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 2.54 (Total Current Assets 2.01b / Total Current Liabilities 788.7m)
Debt / Equity = 0.04 (Debt 72.0m / totalStockholderEquity, last quarter 1.92b)
Debt / EBITDA = -25.89 (Net Debt -671.6m / EBITDA 25.9m)
Debt / FCF = -2.16 (Net Debt -671.6m / FCF TTM 311.6m)
Total Stockholder Equity = 1.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.93% (Net Income 229.7m / Total Assets 2.90b)
RoE = 12.88% (Net Income TTM 229.7m / Total Stockholder Equity 1.78b)
RoCE = 1.22% (EBIT 22.7m / Capital Employed (Equity 1.78b + L.T.Debt 77.8m))
RoIC = 3.21% (EBIT 22.7m / (Assets 2.90b - Curr.Liab 788.7m - Cash 1.40b))
WACC = 11.13% (E(9.99b)/V(10.06b) * Re(11.21%) + (debt cost/tax rate unavailable))
Discount Rate = 11.21% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.09%
[DCF Debug] Terminal Value 66.92% ; FCFE base≈310.4m ; Y1≈300.3m ; Y5≈298.1m
Fair Price DCF = 7.24 (DCF Value 3.29b / Shares Outstanding 453.6m; 5y FCF grow -4.47% → 3.0% )
EPS Correlation: 62.63 | EPS CAGR: 36.37% | SUE: 0.37 | # QB: 0
Revenue Correlation: 84.15 | Revenue CAGR: 9.78% | SUE: 2.05 | # QB: 3
EPS next Quarter (2026-04-30): EPS=0.15 | Chg30d=-0.004 | Revisions Net=+11 | Analysts=17
EPS next Year (2027-01-31): EPS=0.75 | Chg30d=+0.013 | Revisions Net=+0 | Growth EPS=+12.8% | Growth Revenue=+8.9%
Additional Sources for PATH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle